Haptoglobin (HP) Genotyping (INACTIVE as of 02/17/15)
Ordering Recommendation
Polymerase Chain Reaction/Fluorescence Monitoring
Mon, Thu
2-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Consent Form RecommendedConsent Form Recommended
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Interpretive Data:
Background Information for Haptoglobin (HP) Genotyping:
Hp genotype is a predictor of cardiovascular disease in diabetic patients. There is no known correlation between the Hp genotype and cardiovascular risk in nondiabetics. Diabetics with the Hp 2-2 genotype are five times more likely to have cardiovascular disease than those with the Hp 1-1 genotype and may benefit from vitamin E treatment. Diabetics who have the Hp 1-1 genotype are at decreased risk for developing microvascular complications such as nephropathy, retinopathy or for restenosis following percutaneous coronary angioplasty.
Incidence: The Hp 1 and Hp 2 allele frequencies vary across populations. Asians have the highest frequency of Hp 2. The Hp 2-2 genotype is 36 percent in Northwestern Europeans.
Inheritance: Autosomal recessive.
Alleles Tested: Hp 1 and Hp 2.
Clinical Sensitivity: Unknown.
Methodology: Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity: 98 percent.
Limitations:Diagnostic errors can occur due to rare sequence variations. Anhaptoglobinemia (Hp0-0) or hypohaptoglobinemia (Hp 1-0 or Hp 2-0) may be misclassified depending on the cause of lack of gene expression.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
This test is performed pursuant to an agreement with Synvista, Inc.

Compliance Statement C: The performance characteristics of this test were validated by ARUP Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. ARUP is authorized under Clinical Laboratory Improvement Amendments (CLIA) and by all states to perform high-complexity testing. Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

This test is not recommended for the assessment of cardiovascular risk in nondiabetics as there is poor evidence of a correlation between the genotype and cardiovascular risk.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0040127Haptoglobin (HP) Genotyping
2001313HAPTO PCR Specimen
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • HP genotyping